| Identification | Back Directory | [Name]
BMS-243117 | [CAS]
225521-80-2 | [Synonyms]
BMS-243117 MBE6KWV0QI CHEMBL67237 UNII-MBE6KWV0QI BMS243117,BMS 243117 2-(tert-butylcarbamoylamino)-N-(2-chloro-6-methylphenyl)-1,3-benzothiazole-6-carboxamide N-(2-Chloro-6-methylphenyl)-2-[[(tert-butylamino)carbonyl]amino]-6-benzothiazolecarboxamide 6-Benzothiazolecarboxamide, N-(2-chloro-6-methylphenyl)-2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]- | [Molecular Formula]
C20H21ClN4O2S | [MOL File]
225521-80-2.mol | [Molecular Weight]
416.92 |
| Hazard Information | Back Directory | [Uses]
BMS-243117 is a potent, and selective benzothiazole based p56Lck inhibitor with an IC50 of 4 nM. BMS-243117 inhibits anti-CD3/anti-CD28 induced PBL (human peripheral blood T-cells) proliferation with an IC50 of 1.1 μM. BMS-243117 binds in an extended conformation to the ATP-binding site of Lck[1]. | [IC 50]
Lck: 4 nM (IC50); Fyn: 32 nM (IC50); Blk: 84 nM (IC50); Src: 158 nM (IC50); Hck: 960 nM (IC50); Lyn: 330 nM (IC50); Fgr: 60 nM (IC50) | [References]
[1] Jagabandhu Das, et al. Molecular design, synthesis, and structure-Activity relationships leading to the potent and selective p56(lck) inhibitor BMS-243117. Bioorg Med Chem Lett. 2003 Jul 7;13(13):2145-9. DOI:10.1016/s0960-894x(03)00380-9 |
|
|